TrialBMC cancer2022

Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial).

David J Barnes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.